CytoMed Therapeutics (GDTC) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CytoMed Therapeutics (GDTC) has outperformed Medicus Pharma (MDCX) over the past year, losing 56.5% versus a loss of 95.9%. CytoMed Therapeutics is the larger company by market cap ($11.2 million vs $140,316), about 79.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | MDCX |
|---|---|---|
| Share price | $0.9385 | $0.0936 |
| Market cap | $11.20M | $140.32K |
| 1-day change | -0.68% | -8.15% |
| YTD return | -29.22% | -93.34% |
| 1-year return | -56.46% | -95.86% |
| EPS (TTM) | $-0.23 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.68 | $139.00 |
| 52-week low | $0.68 | $0.084 |
| Distance from 52-week high | -74.50% | -99.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +343.26% | +4707.69% |
| Average volume | 78.66K | 92.96K |
| Shares outstanding | 11.93M | 1.50M |
| Employees | 42 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CytoMed Therapeutics is about 79.8 times larger than Medicus Pharma by market value ($11.20M vs $140.32K).
- GDTC has outperformed MDCX by 39.4 percentage points over the past year.
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
GDTC vs MDCX FAQ
Which is bigger, CytoMed Therapeutics or Medicus Pharma?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $11.20M compared with $140.32K for Medicus Pharma (MDCX).
Which stock has performed better over the past year, GDTC or MDCX?
GDTC returned -56.46% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are CytoMed Therapeutics and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.